ABSTRACT: Two cases of granulomatous colitis in two French bulldogs were found to be unresponsive to fluoroquinolones. The granulomatous colitis diagnosis was made on the basis of PAS-positive histiocytes in the lamina propria of the colonic mucosa in biopsy samples taken at colonoscopy. Remission of granulomatous colitis has been reported using fluoroquinolones leading to the idea that invasive Escherichia coli strains in the colonic mucosa are involved. Oral enrofloxacin (Baytril 150 mg, Bayer, Spain) at 10 mg/kg per day for eight weeks was prescribed to both dogs in this study. A first course of therapy resolved the problem in dog No. 1, which, however, was followed by relapse three months later without enrofloxacin response. No clinical remission was seen in dog No. 2 and 4.4 mg/kg marbofloxacin (Marbocyl P 20 mg, Vetoquinol, Spain) per day for 10 weeks was administered but without any response. From both dogs, biopsy samples from the colonic mucosa were taken during colonoscopy. Samples were homogenised for microbial culture in different agar media to identify invasive microbes. Escherichia coli were largely isolated and antibiotic sensitivity testing (MIC of E. coli to selected antimicrobials, CLSI 2013) was carried out. In both cases, E. coli was resistant to fluoroquinolones. In dog No. 1 E. coli was susceptible to amoxicillin-clavulanate, cefazolin, amikacin and gentamicin whereas in dog No. 2 it was susceptible to doxycycline and amoxicillin-clavulanate. Clinical remission was achieved in dog No. 1 with amoxicillin-clavulanate (Synulox 250 mg, Pfizer, Spain) therapy for eight weeks. No response was found in dog No. 2 with any of the antimicrobials alone or combined with metronidazole.
Granulomatous colitis (GC), also known as histiocytic ulcerative colitis, is a chronic inflammation of the colonic mucosa seen in young Boxer dogs (Davis et al. 2004; Craven et al. 2010; Manchester et al. 2013 ) and in French bulldogs, a breed ancestrally related to Boxer dogs ( Van der Gaag et al. 1978; Tanaka et al. 2003; Manchester et al. 2013) . Clinical signs include chronic diarrhoea with increasing frequency of defecation, haematochezia, mucus and tenesmus (Stokes et al. 2001; Hostutler et al. 2004; Craven et al. 2010; Manchester et al. 2013) . Severe cases also exhibit hypoalbuminemia and cachexia (Manchester et al. 2013 ). In the past, most GC cases failed to respond to any therapy. However, since the association between GC and E. coli strains within the colonic mucosa in affected dogs was reported, the condition has been successfully managed with enrofloxacin therapy (Mansfield et al. 2009; Craven et al. 2010; Lechowski et al. 2013; Manchester et al. 2013) . The aim of this study was to describe two cases of GC in French bulldogs that failed to respond to any fluoroquinolone therapy.
Case description
Two privately owned French bulldogs were studied. A female, aged 17 months (dog No. 1), was presented with chronic diarrhoea, with increased frequency of defecation, haematochezia, tenesmus and abdominal pain. A male, aged 11 months (dog No. 2), presented with haematochezia since birth. Both dogs were fed twice a day with diff erent commercial hypoallergenic diets and specifi c diets for gastrointestinal problems and which slightly improved clinical signs. Diff erent therapies with metronidazole, sulfasalazine and prednisolone were prescribed in both cases but without any clinical response. Results of blood and urine analysis were normal in both cases. A thickened colonic mucosa and an enlargement of the regional lymph nodes were detected on ultrasonography surveys. A colonoscopy was performed in both dogs showing an irregular, ulcerated and hyperaemic colonic mucosa. Several biopsies samples were taken to confi rm the diagnosis of GC and thus oral enrofl oxacin (Baytril 150 mg, Bayer, Madrid, Spain) at 10 mg/kg per day for eight weeks was prescribed as recommended (Mansfi eld et al. 2009 ). Dog No. 1 recovered with this therapy but clinical signs relapsed three months later without any clinical response to enrofl oxacin at this time. Dog No. 2 did not respond to the initial course of enrofloxacin therapy and received 4.4 mg/kg marbofloxacin (Marbocyl P 20 mg, Vetoquinol, Madrid, Spain) per day for 10 weeks but again without response. Subsequently, biopsy samples from the colonic mucosa were taken from both dogs, ground and homogenised for microbial culture in diff erent agar media (Blood agar, Chocolate agar, Schaedler agar, Cled, Sabouraud and thioglycolate broths; Idexx Laboratories, Barcelona, Spain) to identify invasive microbes. Predominantly E. coli organisms were isolated and antibiotic sensitivity testing (MIC of E. coli to selected antimicrobials, interpreted by Clinical Laboratory Standards Institute 2013; Idexx Laboratories, Barcelona, Spain) was carried out. In dog No. 1, the E. coli strain was resistant to fl uoroquinolones, doxycycline, tetracycline and trimethoprim-sulphamethoxazole but susceptible to amoxicillin-clavulanate, cefazolin, amikacin and gentamicin. Clinical remission was achieved with oral amoxicillin-clavulanate (Synulox 250 mg, Pfi zer, Madrid, Spain) at 20 mg/kg every 8 h for eight weeks. Th e dog No. 1 remains currently in good condition.
The E. coli strain in dog No. 2 was resistant to fluoroquinolones, tetracycline and trimethoprimsulphamethoxazole but susceptible to doxycycline and amoxicillin-clavulanate. No response was found when oral amoxicillin-clavulanate (Synulox 250 mg, Pfizer, Madrid, Spain) at 20 mg/kg every 8 h was administered alone or combined with oral sulfasalazine at 20 mg/kg every 8 h or when 10 mg/kg per day of oral doxycycline alone and combined with oral metronidazole at 10 mg/kg twice a day were administered. Other combinations of antimicrobials and prednisone were prescribed but none improved the condition of dog No. 2.
DISCUSSION AND CONCLUSIONS
GC is a severe chronic disease mostly seen in Boxer dogs (Mansfi eld et al. 2009; Craven et al. 2010) and French bulldogs (Van der Gaag et al. 1978; Tanaka et al. 2003; Manchester et al. 2013 ). It has also been reported in the Mastiff , Alaskan malamute, Doberman pinscher, English bulldog (Manchester et al. 2013) and Beagle (Carvallo et al. 2015) . Young dogs are predominantly aff ected with clinical signs which are similar to those observed in other forms of chronic colitis (Sherding 2003) . Th e defi nitive GC diagnosis is made on the basis of PAS-positive histiocytes in the lamina propria of the colonic mucosa (Tanaka et al. 2003; Hostutler et al. 2004; Mansfi eld et al. 2009; Craven et al. 2010) . Th e cause of GC is not still clear. In only one report (Manchester et al. 2013) , was GC in French bulldogs associated with the invasion of the colonic mucosa by E. coli. GC in dogs is remarkably breed-specifi c and, thus, a heritable anomaly in mucosa immunity that confers susceptibility to invasion and persistence of invasive E. coli within the colonic mucosa may be an important predisposing factor (Mansfi eld et al. 2009; Craven et al. 2010) . To optimise the treatment of GC a specifi c antimicrobial would be needed to eliminate E. coli within these cells. Its ability to eff ectively penetrate cells to kill E. coli might explain the positive results obtained with enrofl oxacin (Mansfi eld et al. 2009; Craven et al. 2010; Lechowski et al. 2013; Manchester et al. 2013 ).
In the two cases reported here invasive E. coli were isolated from the colonic mucosa and enrofloxacin was prescribed for eight weeks at a dose of 10 mg/kg body weight per day as previously reported (Mansfield et al. 2009; Manchester et al. 2013 ). However, both dogs failed to respond to enrofloxacin therapy although dog No. 1 did respond initially. Further, dog No. 2 also failed to respond to marbofloxacin therapy.
In a previous study in French bulldogs (Manchester et al. 2013) , five out of six dogs were reported to be susceptible to enrofloxacin and one case responded
